CVMD

Welcome to CrownBio’s CVMD Blog where we share our thoughts
on the latest trends and hot stories in CVMD

blog.png

Why the Current Excitement over Krill in CVD?

by Judith Gorski PhD, June 15, 2017 at 01:28 PM | Tags

wc-19.jpg

Krill are small crustaceans found in all the world's oceans, which have been harvested as a human and animal food source for many years, recently for use in dietary supplements. A new collaborative study has demonstrated that a novel long-chain (LC) omega-3 rich phospholipid preparation extracted from krill oil can reduce cardiovascular disease risk.

A Translational NHP Platform Evaluated CVD Benefits

The study by Hals et al utilized type 2 diabetic and dyslipidemic monkeys as a translational platform to address the question would an extended treatment duration with a low to moderate dose of a novel LC-omega-3 affect cholesterol levels and be beneficial in reducing cardiovascular risk?

Over a period of 12 weeks, monkeys were given escalating doses of the purified LC omega-3 rich phospholipid preparation. The novel preparation altered blood lipid profiles in a beneficial manner in dyslipidemic, diabetic monkeys without liver or kidney toxicity.

Long-chain omega-3 fatty acids have long been marketed as dietary supplements promising to reduce the risk of cardiovascular disease, cancer, and inflammatory diseases. More recently pharmaceuticals containing EPA and DHA, such as Omacor/Lovaza, have been approved by the FDA for reduction of triglycerides in patients having “very high” (>500mg/dL) plasma triglyceride levels.

Potential Useful Human Therapy to Normalize Dyslipidemia

From a human translation standpoint, this novel preparation, as a single-agent treatment, can be useful as a therapy to normalize dyslipidemia without significant side-effects. Furthermore, it can also be potentially used in combination with current therapies such as statins and PCSK9 inhibitors, thereby expanding the arsenal of drugs to combat dyslipidemia and cardiovascular disease.

Krill may be small and bottom of the food chain but these results are sure to make a big impact.


Author


Related posts

Cardiomyopathy Treatment in Rodent Models – ADA 2018

At ADA 2018, we shared the latest data on our next generation type 2 diabetes (T2D) and obesity rodent models. This included our latest ZDSD rat studies,...

DGAT2 Inhibition Doesn’t Affect Plasma Triglycerides, VLDL ApoB

In a new study published in Cell Metabolism, McClaren et al utilize a variety of translational models, including both mouse models and non-human primate...

Is an Approved NASH Therapy on the Way?

Non-alcoholic steatohepatitis (NASH) is an unmet medical need with no approved therapies and debilitating consequences for patients. Here’s an overview of...

CVMD-Poster-.jpg